Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
Dentsply Sirona (XRAY)
The company has return on total asset (ROA) of 0.0241 % which means that it generated a profit of $0.0241 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0372) %, meaning that it created substantial loss on money invested by shareholders. Dentsply Sirona's management efficiency ratios could be used to measure how well Dentsply Sirona manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.04 in 2024. Return On Capital Employed is likely to drop to 0.05 in 2024. At this time, Dentsply Sirona's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 271.9 M in 2024, whereas Total Assets are likely to drop slightly above 3.7 B in 2024. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.39 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Dentsply Sirona's market, we take the total number of its shares issued and multiply it by Dentsply Sirona's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Dentsply Sirona shows a prevailing Real Value of $37.11 per share. The current price of the firm is $30.5. Our model computes the value of Dentsply Sirona from reviewing the firm fundamentals such as Shares Outstanding of 207.63 M, current valuation of 8.34 B, and Profit Margin of (0.03) % as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Baxter International (BAX)
The company has Return on Asset of 0.0334 % which means that on every $100 spent on assets, it made $0.0334 of profit. This is way below average. Baxter International's management efficiency ratios could be used to measure how well Baxter International manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Baxter International's Return On Tangible Assets are fairly stable compared to the past year. Return On Equity is likely to rise to 0.33 in 2024, whereas Return On Capital Employed is likely to drop 0.02 in 2024. At this time, Baxter International's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 6.4 B in 2024, whereas Total Assets are likely to drop slightly above 16.2 B in 2024. This firm currently falls under 'Large-Cap' category with a total capitalization of 20.15 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Baxter International's market, we take the total number of its shares issued and multiply it by Baxter International's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has Return on Asset of 0.0264 % which means that on every $100 spent on assets, it made $0.0264 of profit. This is way below average. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.01. The value of Return On Capital Employed is expected to slide to 0.04. At this time, Merck's Non Current Liabilities Total is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 10.8 B this year, although the value of Total Current Liabilities will most likely fall to about 13.3 B. The entity currently falls under 'Mega-Cap' category with a total capitalization of 316.78 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Merck's market, we take the total number of its shares issued and multiply it by Merck's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be fairly valued. Merck Company secures a last-minute Real Value of $121.16 per share. The latest price of the firm is $125.78. Our model forecasts the value of Merck Company from analyzing the firm fundamentals such as Current Valuation of 345.96 B, return on equity of 0.009, and Profit Margin of 0.01 % as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend picking up undervalued stocks and discarding overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Intuitive Surgical (ISRG)
The company has return on total asset (ROA) of 0.0777 % which means that it generated a profit of $0.0777 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1483 %, meaning that it created $0.1483 on every $100 dollars invested by stockholders. Intuitive Surgical's management efficiency ratios could be used to measure how well Intuitive Surgical manages its routine affairs as well as how well it operates its assets and liabilities. The Intuitive Surgical's current Return On Tangible Assets is estimated to increase to 0.13. The Intuitive Surgical's current Return On Capital Employed is estimated to increase to 0.13. At this time, Intuitive Surgical's Other Current Assets are most likely to increase significantly in the upcoming years. The Intuitive Surgical's current Total Current Assets is estimated to increase to about 8.3 B, while Other Assets are projected to decrease to roughly 1.1 B. The entity currently falls under 'Mega-Cap' category with a current market capitalization of 134.18 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Intuitive Surgical's market, we take the total number of its shares issued and multiply it by Intuitive Surgical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
94.29 Million
At this time, Intuitive Surgical's Short and Long Term Debt Total is most likely to increase significantly in the upcoming years.
ResMed Inc (RMD)
The company has Return on Asset of 0.1119 % which means that on every $100 spent on assets, it made $0.1119 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2166 %, implying that it generated $0.2166 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to 0.13. In addition to that, Return On Capital Employed is expected to decline to 0.14. At present, ResMed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 477.5 M, whereas Deferred Long Term Asset Charges is forecasted to decline to about 42.6 M. This firm currently falls under 'Large-Cap' category with a total capitalization of 27.19 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ResMed's market, we take the total number of its shares issued and multiply it by ResMed's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the company appears to be fairly valued. ResMed Inc holds a recent Real Value of $182.59 per share. The prevailing price of the company is $178.85. Our model determines the value of ResMed Inc from analyzing the company fundamentals such as Shares Outstanding of 147.09 M, operating margin of 0.29 %, and Return On Equity of 0.22 as well as examining its technical indicators and probability of bankruptcy. In general, most investors support purchasing undervalued entities and exiting overvalued entities since, at some point, asset prices and their ongoing real values will merge together.
Varian Medical Systems (VAR)
The company has Return on Asset of 5.92 % which means that on every $100 spent on assets, it made $5.92 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 13.51 %, implying that it generated $13.51 on every 100 dollars invested. Varian Medical's management efficiency ratios could be used to measure how well Varian Medical manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Large-Cap' category with a total capitalization of 16.27 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Varian Medical's market, we take the total number of its shares issued and multiply it by Varian Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Hologic (HOLX)
The company has return on total asset (ROA) of 0.0649 % which means that it generated a profit of $0.0649 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1057 %, meaning that it created $0.1057 on every $100 dollars invested by stockholders. Hologic's management efficiency ratios could be used to measure how well Hologic manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Hologic's Return On Tangible Assets are fairly stable compared to the past year. Return On Equity is likely to rise to 0.09 in 2024, whereas Return On Capital Employed is likely to drop 0.08 in 2024. At this time, Hologic's Asset Turnover is fairly stable compared to the past year. The entity currently falls under 'Large-Cap' category with a current market capitalization of 17.63 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hologic's market, we take the total number of its shares issued and multiply it by Hologic's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Hologic retains a regular Real Value of $80.89 per share. The prevalent price of the firm is $75.1. Our model calculates the value of Hologic from evaluating the firm fundamentals such as Return On Equity of 0.11, current valuation of 18.27 B, and Return On Asset of 0.0649 as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage acquiring undervalued assets and dropping overvalued assets since, at some point, asset prices and their ongoing real values will come together.
Edwards Lifesciences Corp (EW)
The company has Return on Asset (ROA) of 0.1225 % which means that for every $100 of assets, it generated a profit of $0.1225. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.2234 %, which means that it produced $0.2234 on every 100 dollars invested by current stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.1 in 2024. Return On Capital Employed is likely to drop to 0.14 in 2024. At this time, Edwards Lifesciences' Intangibles To Total Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to climb to 4.91 in 2024, whereas Debt To Assets are likely to drop 0.07 in 2024. The firm currently falls under 'Large-Cap' category with a market capitalization of 52.04 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Edwards Lifesciences's market, we take the total number of its shares issued and multiply it by Edwards Lifesciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Macroaxis Gross Profit
Macroaxis Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Macroaxis previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Macroaxis Gross Profit growth over the last 10 years. Please check Macroaxis' gross profit and other fundamental indicators for more details.
Story appears to be empty
Dentsply Sirona (XRAY)
The company has return on total asset (ROA) of 0.0241 % which means that it generated a profit of $0.0241 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0372) %, meaning that it created substantial loss on money invested by shareholders. Dentsply Sirona's management efficiency ratios could be used to measure how well Dentsply Sirona manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.04 in 2024. Return On Capital Employed is likely to drop to 0.05 in 2024. At this time, Dentsply Sirona's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 271.9 M in 2024, whereas Total Assets are likely to drop slightly above 3.7 B in 2024. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.39 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Dentsply Sirona's market, we take the total number of its shares issued and multiply it by Dentsply Sirona's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Dentsply Sirona shows a prevailing Real Value of $37.11 per share. The current price of the firm is $30.5. Our model computes the value of Dentsply Sirona from reviewing the firm fundamentals such as Shares Outstanding of 207.63 M, current valuation of 8.34 B, and Profit Margin of (0.03) % as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Baxter International (BAX)
The company has Return on Asset of 0.0334 % which means that on every $100 spent on assets, it made $0.0334 of profit. This is way below average. Baxter International's management efficiency ratios could be used to measure how well Baxter International manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Baxter International's Return On Tangible Assets are fairly stable compared to the past year. Return On Equity is likely to rise to 0.33 in 2024, whereas Return On Capital Employed is likely to drop 0.02 in 2024. At this time, Baxter International's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 6.4 B in 2024, whereas Total Assets are likely to drop slightly above 16.2 B in 2024. This firm currently falls under 'Large-Cap' category with a total capitalization of 20.15 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Baxter International's market, we take the total number of its shares issued and multiply it by Baxter International's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has Return on Asset of 0.0264 % which means that on every $100 spent on assets, it made $0.0264 of profit. This is way below average. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.01. The value of Return On Capital Employed is expected to slide to 0.04. At this time, Merck's Non Current Liabilities Total is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 10.8 B this year, although the value of Total Current Liabilities will most likely fall to about 13.3 B. The entity currently falls under 'Mega-Cap' category with a total capitalization of 316.78 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Merck's market, we take the total number of its shares issued and multiply it by Merck's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be fairly valued. Merck Company secures a last-minute Real Value of $121.16 per share. The latest price of the firm is $125.78. Our model forecasts the value of Merck Company from analyzing the firm fundamentals such as Current Valuation of 345.96 B, return on equity of 0.009, and Profit Margin of 0.01 % as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend picking up undervalued stocks and discarding overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Intuitive Surgical (ISRG)
The company has return on total asset (ROA) of 0.0777 % which means that it generated a profit of $0.0777 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1483 %, meaning that it created $0.1483 on every $100 dollars invested by stockholders. Intuitive Surgical's management efficiency ratios could be used to measure how well Intuitive Surgical manages its routine affairs as well as how well it operates its assets and liabilities. The Intuitive Surgical's current Return On Tangible Assets is estimated to increase to 0.13. The Intuitive Surgical's current Return On Capital Employed is estimated to increase to 0.13. At this time, Intuitive Surgical's Other Current Assets are most likely to increase significantly in the upcoming years. The Intuitive Surgical's current Total Current Assets is estimated to increase to about 8.3 B, while Other Assets are projected to decrease to roughly 1.1 B. The entity currently falls under 'Mega-Cap' category with a current market capitalization of 134.18 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Intuitive Surgical's market, we take the total number of its shares issued and multiply it by Intuitive Surgical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
94.29 Million
At this time, Intuitive Surgical's Short and Long Term Debt Total is most likely to increase significantly in the upcoming years.
ResMed Inc (RMD)
The company has Return on Asset of 0.1119 % which means that on every $100 spent on assets, it made $0.1119 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2166 %, implying that it generated $0.2166 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to 0.13. In addition to that, Return On Capital Employed is expected to decline to 0.14. At present, ResMed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 477.5 M, whereas Deferred Long Term Asset Charges is forecasted to decline to about 42.6 M. This firm currently falls under 'Large-Cap' category with a total capitalization of 27.19 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ResMed's market, we take the total number of its shares issued and multiply it by ResMed's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the company appears to be fairly valued. ResMed Inc holds a recent Real Value of $182.59 per share. The prevailing price of the company is $178.85. Our model determines the value of ResMed Inc from analyzing the company fundamentals such as Shares Outstanding of 147.09 M, operating margin of 0.29 %, and Return On Equity of 0.22 as well as examining its technical indicators and probability of bankruptcy. In general, most investors support purchasing undervalued entities and exiting overvalued entities since, at some point, asset prices and their ongoing real values will merge together.
Varian Medical Systems (VAR)
The company has Return on Asset of 5.92 % which means that on every $100 spent on assets, it made $5.92 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 13.51 %, implying that it generated $13.51 on every 100 dollars invested. Varian Medical's management efficiency ratios could be used to measure how well Varian Medical manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Large-Cap' category with a total capitalization of 16.27 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Varian Medical's market, we take the total number of its shares issued and multiply it by Varian Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Hologic (HOLX)
The company has return on total asset (ROA) of 0.0649 % which means that it generated a profit of $0.0649 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1057 %, meaning that it created $0.1057 on every $100 dollars invested by stockholders. Hologic's management efficiency ratios could be used to measure how well Hologic manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Hologic's Return On Tangible Assets are fairly stable compared to the past year. Return On Equity is likely to rise to 0.09 in 2024, whereas Return On Capital Employed is likely to drop 0.08 in 2024. At this time, Hologic's Asset Turnover is fairly stable compared to the past year. The entity currently falls under 'Large-Cap' category with a current market capitalization of 17.63 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hologic's market, we take the total number of its shares issued and multiply it by Hologic's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Hologic retains a regular Real Value of $80.89 per share. The prevalent price of the firm is $75.1. Our model calculates the value of Hologic from evaluating the firm fundamentals such as Return On Equity of 0.11, current valuation of 18.27 B, and Return On Asset of 0.0649 as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage acquiring undervalued assets and dropping overvalued assets since, at some point, asset prices and their ongoing real values will come together.
Edwards Lifesciences Corp (EW)
The company has Return on Asset (ROA) of 0.1225 % which means that for every $100 of assets, it generated a profit of $0.1225. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.2234 %, which means that it produced $0.2234 on every 100 dollars invested by current stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.1 in 2024. Return On Capital Employed is likely to drop to 0.14 in 2024. At this time, Edwards Lifesciences' Intangibles To Total Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to climb to 4.91 in 2024, whereas Debt To Assets are likely to drop 0.07 in 2024. The firm currently falls under 'Large-Cap' category with a market capitalization of 52.04 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Edwards Lifesciences's market, we take the total number of its shares issued and multiply it by Edwards Lifesciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Sync Your Broker Now
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
